BioHealth Innovation inked a pair of recent deals to run incubators in Montgomery County.
The Rockville-based organization that works to help health and life sciences startups in the region is set to manage the Germantown Innovation Center and the Rockville Innovation Center. It’s the first foray into running incubators for the public-private partnership, which also helps startups coming out of UMB and Johns Hopkins in Baltimore.
University of Maryland (UM) Ventures and CoapTech, LLC, announced today that the University of Maryland, Baltimore (UMB) has granted CoapTech exclusive licensing rights for the commercial development of a platform technology called Coaptive Ultrasound. CoapTech will use the technology, initially, to bring to market a medical device allowing non-surgical providers to safely perform feeding tube placement at the bedside through a novel procedure termed PUG (Percutaneous Ultrasound Gastrostomy). PUG is a minimally invasive and more cost-effective method for the placement of permanent gastrostomy (feeding) tubes into stomachs of patients who need long-term nutritional supplementation.
WorkSource Montgomery, Inc., the workforce development resource for Montgomery County businesses and career seekers, is collaborating with Montgomery College, which will serve as the lead on a $5.6 million America’s Promise grant. The grant will provide IT and cybersecurity training for students to ensure Montgomery County is better equipped to meet local business needs.
MedImmune and Abpro said today they will partner to develop a preclinical, novel, bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF).
Through the collaboration—whose value was not disclosed—several potential therapeutic areas will be explored where inhibition of the Ang2 and VEGF pathways with the bispecific antibody may provide clinical benefit, MedImmune and Abpro said.
Investigators at the Institute for Clinical Research and Health Policy Studies (ICRHPS) at Tufts Medical Center (Tufts MC) and Tufts Clinical and Translational Science Institute (CTSI) – a shared resource between Tufts Medical Center and Tufts University School of Medicine (TUSM), together with the Johns Hopkins University (JHU) School of Medicine’s Brain Injury Outcomes (BIOS) Division and the Institute for Clinical and Translational Research (ICTR), won a seven-year, $25 million award from the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to form one of only three new national Trial Innovation Centers (TICs) that will provide high-quality design and operational support to investigators conducting multi-center clinical trials.
Marriott Hotels in Europe has launched an accelerator program for tech companies to enhance the travel and hospitality experience. Each startup will be given expert guidance and the opportunity to pilot their product. Following a successful test period, Marriott Hotels could potentially offer them an ongoing partnership.
AstraZeneca will partner with Bicycle Therapeutics to develop respiratory, cardiovascular, and metabolic disease treatments based on Bicycle’s proprietary bicyclic peptide (Bicycle®) product platform through a collaboration that the Cambridge, U.K., startup said today could generate for it more than $1 billion.
Under the collaboration, Bicycle has agreed to identify Bicycle bicyclic peptides for an undisclosed number of targets specified by AstraZeneca. The pharma giant has agreed to oversee further development and product commercialization.
Becton, Dickinson and Co. (NYSE:BDX) presented their roadmap for the future on their recent analyst day briefing. The presentation laid out ambitious plans that management has set out for the company through to 2019, including targeting top line expansion and double-digit bottom line expansion to be driven by margin improvements. The management has also set out to increase dividends through to 2019, through roughly $11 billion in operating cash flow (OCF) generation.
BioBuzz Workforce Foundation, Inc., a social community organization whose mission is to build a more connected bioscience industry in the region, today announced a partnership with The City of Frederick Department of Economic Development and the Frederick County Chapter of BioBeers Meetup group. This new collaboration will give Frederick companies access to BioBuzz’s BioHive Platform and showcase them as important components within the ecosystem.
QIAGEN and CosmosID, a leading genomic big data company, today announced the launch of a metagenomics analysis plugin for the QIAGEN Microbial Genomics Pro Suite and CLC Genomics Workbench. The launch of the Cosmos ID plugin expands QIAGEN’s industry leading platform for NGS bioinformatics and strengthens its role as a provider of Sample to Insight metagenomics solutions.
Seeking to deliver the “final nail in the coffin for HIV,” NIH scientists have kicked off a large clinical trial of a vaccine regimen this week in South Africa.
Under a collaboration that includes GlaxoSmithKline and Sanofi Pasteur, the National Institute of Allergy and Infectious Diseases started a phase 2b/3 trial of a new vaccine regimen in 5,400 sexually active men and women aged 18 to 35 who don’t have the infection. They’ll receive five injections over a year.
A five-year extension of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs took a big step forward at the end of November.
U.S. Sen. Jeanne Shaheen, D-NH, announced that language she wrote seeking the extension was included in a compromise National Defense Authorization Act, with votes expected soon.
This request for information (RFI) seeks comments regarding early translational research activities supported by NHLBI.
Background
NHLBI seeks to facilitate and accelerate the development of new clinical interventions by bridging the gaps between mechanistic, discovery, and early translational research. This includes providing appropriate mechanisms to support investigator-initiated research, addressing resource and knowledge gaps, and creating initiatives to support career development of translational scientists and biomedical entrepreneurs.
The emergence of big data, as well as advancements in data science approaches and technology, is providing pharmaceutical companies with an opportunity to gain novel insights that can enhance and accelerate drug development. It will increasingly help government health agencies, payers, and providers to make decisions about such issues as drug discovery, patient access, and marketing. From our unique vantage points at Genentech, a leading biotechnology company with a major data science practice, and The Data Incubator, a data-science education company that places and trains data scientists, we have seen how the pharmaceuticals industry has leveraged big data for some potentially revolutionary advances and the challenges it has faced along the way.
In its third year of mentoring and investing in cybersecurity start-ups in Northern Virginia, state-funded start-up accelerator Mach37 is starting to show it can churn out self-sustaining businesses.
Quasi-public venture capital firm MassVentures reports that its SBIR Targeted Technologies (START) program has invested $12 million into 50 companies that need more time to commercialize high-risk, high-reward technologies — and those companies have leveraged that state investment to raise an additional $278 million in outside capital.
Scientific efforts to find cures for cancer will be severely hampered if the scientific community does not change the ways in which patient data is collected, shared, and analyzed. The development of targeted therapies and immunotherapies — the two biggest hopes for cancer cures — depend on the existence of large data sets comprising patients’ genetic and clinical information. Today, that data is fragmented and guarded in silos. Indeed, the well-kept secret in the cancer space is that progress in finding cures is being impeded as much by the lack of sharing by the players in the precision medicine ecosystem as it is by the stubbornness of the underlying science.
Sean Parker decided to take on cancer by throwing so many deep-rooted basics of research tradition out the window that he very nearly drove away the academics he wanted to attract.
As part of its longstanding commitment to Africa, Johnson & Johnson today announced the launch of the Africa Innovation Challenge, an initiative to support Africa’s vibrant and growing innovation ecosystem and to help develop important and locally sustainable consumer health solutions. The challenge is the latest initiative in the company’s comprehensive approach to advancing health and innovation worldwide. The Johnson & Johnson Family of Companies’ presence in Africa dates back more than 80 years and includes business operations, public health programs and corporate citizenship.
What do those things have to do with the repeal of the Affordable Care Act?
Economists and policymakers think the U.S. may be overpaying for such services, which helps drive up healthcare expenses for everyone. And the health law has a program that includes testing new ways to pay for care — including in those three areas — that might result in better quality and lower costs.
Buyout firms have taken an increasingly large role in healthcare, investing in the full range of companies: insurers, hospitals, pharmaceutical companies, medical-technology firms, and many kinds of service provider. Historically, success has come from making “smart bets” on companies well positioned to capitalize on an industry trend or shift. TPG’s buyout of Par Pharmaceutical and Clayton, Dubilier & Rice’s acquisition of Envision Healthcare are examples of investments that benefited from secular industry tailwinds. Those same factors have propelled the healthcare sector to a leading performance in public markets over the past five years (Exhibit 1).
America’s entrepreneurial economy is the envy of the world. Young companies account for almost 30 percent of new jobs, and as we have fought back from the worst economic crisis of our lifetimes, startups have helped the U.S. private sector create 15.5 million jobs since early 2010—the longest streak of private-sector job creation on record.
Today, in celebration of National Entrepreneurship Month, the Administration is releasing a Top 10 list of President Obama’s most significant specific actions to promote American entrepreneurship, as well as announcing new efforts to build on these successes. The President’s unprecedented focus on the role of startups in the United States’ innovation economy is exemplified by his launch of Startup America in 2011, a White House initiative to celebrate, inspire, and accelerate high-growth entrepreneurship throughout the Nation.
Venture capital has been on a good run over the past few years across a range of sectors; even with recent slowdown relative to 2014-2015, venture-backed investments remain above historic averages. In fact, the first three quarters of 2016 alone are already higher than the annual rate of venture investing in all but two years since 2002.
Montgomery Community Media in partnership with the Maryland/DC District Export Council, the US Commercial Service, the Maryland Department of Commerce, and the Small Business Administration present a three-hour program on the challenges and opportunities facing companies going global. The program will feature 3 panels covering key aspects of international trade, including trade finance and local resources that facilitate trade. Speakers include government executives as well as CEOs who have successfully taken their companies international.
Wednesday, December 14, 7 – 11 amFalls Church Marriott Fairview Park
Super Early Bird expires November 3rd for our CONNECTpreneur Winter Forum, headlined by Revolution Chairman & CEO, STEVE CASE, former AOL Time Warner Chair and New York Times bestselling author of The Third Wave.
The Big Idea CONNECTpreneur FORUM has been called “The Best Networking Event in DC.” DCInno calls CONNECTpreneur a “NETWORKING JACKPOT” of the DC Region’s TOP Entrepreneurs, Business Leaders, CXOs, Angels, and VCs.
Dear Friends and Colleagues, This next DC SoPE event is a must for every healthcare/life science entrepreneur, innovator, and potential investor! Our panel will answer questions about terms sheets from the audience…from the most basic to the most erudite. Please join us and pass the information along to your constituents and stakeholders. Thanks for your support in nurturing the Healthcare/Life science ecosystem in the DC region.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
